alone (CH arm: n=182) or with bevacizumab (BEV + CH arm: n=179). 11 Chemotherapy included paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan. Adding bevacizumab to chemotherapy significantly improved PFS, with a median PFS of 6.7 months (95
Search Results
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy
Justine Lequesne, Florence Joly, Julien Peron, Isabelle Ray-Coquard, Anne-Claire Hardy-Bessard, Frédéric Selle, Dominique Berton, Philippe Follana, Michel Fabbro, Alain Lortholary, Eric Pujade-Lauraine, Sophie Lefèvre-Arbogast, and Elodie Coquan
Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study
John H. Strickler, Ling-I Hsu, Phoebe Wright, Michael Stecher, Muriel F. Siadak, Maria Corinna Palanca-Wessels, Junhua Yu, Nicole Zhang, Carin R. Espenschied, Kathryn Lang, and Tanios S. Bekaii-Saab
follows: chemotherapy; anti-EGFR therapy ± chemotherapy; anti-VEGF therapy ± chemotherapy; HER2-directed therapy; tipiracil + trifluridine; regorafenib; and non–NCCN-recommended therapies (which included paclitaxel, carboplatin, cisplatin, gemcitabine
Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?
Amit Mahipal, Minsig Choi, and Richard Kim
to poor accrual. In the 40 patients studied, survival was significantly longer in the irinotecan arm (median OS, 4.0 vs 2.4 months). Tumor-related symptoms were significantly improved in the experimental arm. Other single agents, such as paclitaxel
Avastin, ODAC, and the FDA: Are We Drafting the Right Players?
Harold J. Burstein
provide confirmatory evidence supporting the original ECOG 2100 study that had led to accelerated approval of bevacizumab in combination with paclitaxel for advanced breast cancer. The FDA will decide in September whether to withdraw the label for the
Practice-Changing Interventions in the Systemic Management of Breast Cancer
Presented by: William J. Gradishar
are given earlier in the course of metastatic disease rather than later, he added. Less frequently, microsatellite instability–high (MSI-H) status can also be exploited with the anti–PD-L1 agent atezolizumab + nab-paclitaxel. The rate NTRK fusions
Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management
Zhi Ven Fong and Cristina R. Ferrone
horizon for patients with metastatic PDAC significantly changed with the multiagent chemotherapy regimens fluorouracil/folinic acid/irinotecan/oxaliplatin (FOLFIRINOX) 4 and gemcitabine/nab-paclitaxel, 5 respectively. Median survival for patients with
Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
A. Dimitrios Colevas
SCCHN. 9 - 15 The most robustly studied agents are cisplatin, carboplatin, methotrexate, 5-fluorouracil (5-FU), ifosfamide, paclitaxel, and docetaxel ( Table 1 ). Response rates typically range from 10% to 30%, with some outlier reports of higher
Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer
Michael Xiang, A. Dimitrios Colevas, F. Christopher Holsinger, Quynh-Thu X. Le, and Beth M. Beadle
combination chemotherapy ( Figure 2A ), which was predominantly with paclitaxel. By contrast, 86% of patients in the cisplatin cohort received cisplatin monotherapy ( Figure 2B ). H&N CSM was higher for single-agent carboplatin than for multiagent chemotherapy
Impact of the Identification of Nonhuman Genetic Signatures in the Diagnosis and Management of Carcinoma of Unknown Primary
Arantzazu Barquín García, Sara Palacios-Zambrano, Felipe Lozano Alarcón, Beatriz Paumard-Hernández, Miguel Quiralte Pulido, Paloma Navarro, Laura Rodríguez, Isabel Salas Villar, and Jesús García-Donas
. With these results, breast and urothelial carcinoma were excluded. After the patient was diagnosed with a stage IV tumor of unknown primary, first-line chemotherapy treatment was started with carboplatin at area under the curve 5 and paclitaxel at 175
Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh Nguyen, Jamie Koo, Jon H. Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil Dasyam, and Nathan Bahary
regimens, including gemcitabine plus nab-paclitaxel and FOLFIRINOX (5-fluorouracil, folinic acid, oxaliplatin, and irinotecan), have limited efficacy, with an incremental survival benefit of only a few months in unselected patients. However, significant